Serotonergic and dopaminergic neuroendocrine responses of male depressive patients before and after a therapeutic ECT course

Electroconvulsive therapy (ECT) is an effective treatment for major depressive illness, even for patients who do not respond to antidepressant drugs. According to the prevailing neurophysiological hypotheses for depression, it can be expected that an ECT therapeutic course modulates the responsivity...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European archives of psychiatry and clinical neuroscience 2002-08, Vol.252 (4), p.172-176
Hauptverfasser: Markianos, Manolis, Hatzimanolis, John, Lykouras, Lefteris
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 176
container_issue 4
container_start_page 172
container_title European archives of psychiatry and clinical neuroscience
container_volume 252
creator Markianos, Manolis
Hatzimanolis, John
Lykouras, Lefteris
description Electroconvulsive therapy (ECT) is an effective treatment for major depressive illness, even for patients who do not respond to antidepressant drugs. According to the prevailing neurophysiological hypotheses for depression, it can be expected that an ECT therapeutic course modulates the responsivity of central neurotransmitter systems, but the results up to now have been inconclusive. To test such hypotheses, we studied possible changes in the serotonergic and in dopaminergic systems' responsivity in 11 male patients with major depression by performing neuroendocrine challenge tests before and after a therapeutic ECT course. Serotonergic responsivity was assessed by measuring the prolactin and cortisol responses to i. v. administration of the serotonin uptake inhibitor clomipramine (CMI test), and dopaminergic responsivity by measuring the prolactin responses to the dopamine receptor blocker haloperidol (HAL test), administered intramuscularly. The prolactin and cortisol responses during the first and the last ECT of the course (8 to 13 sessions) were also assessed. The CMI and HAL tests were also performed in 13 male healthy subjects. The prolactin responses to CMI were significantly blunted in the patient group compared to the control group, and remained unaltered at the end of the ECT course, although the depressive symptomatology was substantially reduced from 27.8 +/- 7.1 to 4.8 +/- 2.3 points in the Hamilton Depression Rating Scale. The cortisol responses to CMI were blunted before the ECT course compared to controls, but not after the course: there was a moderate increase of cortisol at + 30 min in the CMI test after the ECT course compared to that before ECT (p = 0.05). The prolactin and cortisol responses to the electrical stimulus during the first and the last ECT were identical. The strong therapeutic effect of ECT in depression, observed already at the end of the course, is not a result of considerable modifications in central serotonergic or dopaminergic responsivity, as revealed by the neuroendocrine challenge tests and the hormone responses to the electrical stimulus. The enhancement of the cortisol responses to CMI after the course may indicate a moderate increase in 5-HT1A receptor responsivity.
doi_str_mv 10.1007/s00406-002-0378-1
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72108915</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>690294651</sourcerecordid><originalsourceid>FETCH-LOGICAL-c324t-f7b0260f8709e57f50ef5930f8de46d1377ce8fe267974f0abe4e6e5cfdbae893</originalsourceid><addsrcrecordid>eNpdkUtLxDAUhYMozjj6A9xIcOGuevNo0y5lGB8w4MJxHdL2RjtMm5q0guCPNzoFwdWFj3MOFz5CzhlcMwB1EwAkZAkAT0CoPGEHZM6kEEkuC3ZI5lBISJgQckZOQtgCAEs5HJMZ41zyVOVz8vWM3g2uQ__aVNR0Na1db9pmAh2O3mFXu8pHRD2G3nUBA3WWtmaHtMY-wtB8IO3N0GA3BFqidR5_x4wd0FNDhzf0psdxiJur5YZWbvQBT8mRNbuAZ9NdkJe71Wb5kKyf7h-Xt-ukElwOiVUl8AxsrqDAVNkU0KaFiKBGmdVMKFVhbpFnqlDSgilRYoZpZevSYF6IBbna7_bevY8YBt02ocLdznToxqAVZ5AXLI3By3_BbXy0i79pziRL8yLLYojtQ5V3IXi0uvdNa_ynZqB_vOi9Fx296B8vmsXOxTQ8li3Wf41JhPgGyYCK9A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214158966</pqid></control><display><type>article</type><title>Serotonergic and dopaminergic neuroendocrine responses of male depressive patients before and after a therapeutic ECT course</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Markianos, Manolis ; Hatzimanolis, John ; Lykouras, Lefteris</creator><creatorcontrib>Markianos, Manolis ; Hatzimanolis, John ; Lykouras, Lefteris</creatorcontrib><description>Electroconvulsive therapy (ECT) is an effective treatment for major depressive illness, even for patients who do not respond to antidepressant drugs. According to the prevailing neurophysiological hypotheses for depression, it can be expected that an ECT therapeutic course modulates the responsivity of central neurotransmitter systems, but the results up to now have been inconclusive. To test such hypotheses, we studied possible changes in the serotonergic and in dopaminergic systems' responsivity in 11 male patients with major depression by performing neuroendocrine challenge tests before and after a therapeutic ECT course. Serotonergic responsivity was assessed by measuring the prolactin and cortisol responses to i. v. administration of the serotonin uptake inhibitor clomipramine (CMI test), and dopaminergic responsivity by measuring the prolactin responses to the dopamine receptor blocker haloperidol (HAL test), administered intramuscularly. The prolactin and cortisol responses during the first and the last ECT of the course (8 to 13 sessions) were also assessed. The CMI and HAL tests were also performed in 13 male healthy subjects. The prolactin responses to CMI were significantly blunted in the patient group compared to the control group, and remained unaltered at the end of the ECT course, although the depressive symptomatology was substantially reduced from 27.8 +/- 7.1 to 4.8 +/- 2.3 points in the Hamilton Depression Rating Scale. The cortisol responses to CMI were blunted before the ECT course compared to controls, but not after the course: there was a moderate increase of cortisol at + 30 min in the CMI test after the ECT course compared to that before ECT (p = 0.05). The prolactin and cortisol responses to the electrical stimulus during the first and the last ECT were identical. The strong therapeutic effect of ECT in depression, observed already at the end of the course, is not a result of considerable modifications in central serotonergic or dopaminergic responsivity, as revealed by the neuroendocrine challenge tests and the hormone responses to the electrical stimulus. The enhancement of the cortisol responses to CMI after the course may indicate a moderate increase in 5-HT1A receptor responsivity.</description><identifier>ISSN: 0940-1334</identifier><identifier>EISSN: 1433-8491</identifier><identifier>DOI: 10.1007/s00406-002-0378-1</identifier><identifier>PMID: 12242578</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Adult ; Aged ; Clomipramine - pharmacology ; Depressive Disorder, Major - blood ; Depressive Disorder, Major - therapy ; Dopamine Antagonists - pharmacology ; Electroconvulsive Therapy - methods ; Haloperidol - pharmacology ; Humans ; Hydrocortisone - blood ; Male ; Middle Aged ; Prolactin - blood ; Psychiatric Status Rating Scales ; Serotonin Uptake Inhibitors - pharmacology ; Treatment Outcome</subject><ispartof>European archives of psychiatry and clinical neuroscience, 2002-08, Vol.252 (4), p.172-176</ispartof><rights>Copyright Springer-Verlag 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c324t-f7b0260f8709e57f50ef5930f8de46d1377ce8fe267974f0abe4e6e5cfdbae893</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12242578$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Markianos, Manolis</creatorcontrib><creatorcontrib>Hatzimanolis, John</creatorcontrib><creatorcontrib>Lykouras, Lefteris</creatorcontrib><title>Serotonergic and dopaminergic neuroendocrine responses of male depressive patients before and after a therapeutic ECT course</title><title>European archives of psychiatry and clinical neuroscience</title><addtitle>Eur Arch Psychiatry Clin Neurosci</addtitle><description>Electroconvulsive therapy (ECT) is an effective treatment for major depressive illness, even for patients who do not respond to antidepressant drugs. According to the prevailing neurophysiological hypotheses for depression, it can be expected that an ECT therapeutic course modulates the responsivity of central neurotransmitter systems, but the results up to now have been inconclusive. To test such hypotheses, we studied possible changes in the serotonergic and in dopaminergic systems' responsivity in 11 male patients with major depression by performing neuroendocrine challenge tests before and after a therapeutic ECT course. Serotonergic responsivity was assessed by measuring the prolactin and cortisol responses to i. v. administration of the serotonin uptake inhibitor clomipramine (CMI test), and dopaminergic responsivity by measuring the prolactin responses to the dopamine receptor blocker haloperidol (HAL test), administered intramuscularly. The prolactin and cortisol responses during the first and the last ECT of the course (8 to 13 sessions) were also assessed. The CMI and HAL tests were also performed in 13 male healthy subjects. The prolactin responses to CMI were significantly blunted in the patient group compared to the control group, and remained unaltered at the end of the ECT course, although the depressive symptomatology was substantially reduced from 27.8 +/- 7.1 to 4.8 +/- 2.3 points in the Hamilton Depression Rating Scale. The cortisol responses to CMI were blunted before the ECT course compared to controls, but not after the course: there was a moderate increase of cortisol at + 30 min in the CMI test after the ECT course compared to that before ECT (p = 0.05). The prolactin and cortisol responses to the electrical stimulus during the first and the last ECT were identical. The strong therapeutic effect of ECT in depression, observed already at the end of the course, is not a result of considerable modifications in central serotonergic or dopaminergic responsivity, as revealed by the neuroendocrine challenge tests and the hormone responses to the electrical stimulus. The enhancement of the cortisol responses to CMI after the course may indicate a moderate increase in 5-HT1A receptor responsivity.</description><subject>Adult</subject><subject>Aged</subject><subject>Clomipramine - pharmacology</subject><subject>Depressive Disorder, Major - blood</subject><subject>Depressive Disorder, Major - therapy</subject><subject>Dopamine Antagonists - pharmacology</subject><subject>Electroconvulsive Therapy - methods</subject><subject>Haloperidol - pharmacology</subject><subject>Humans</subject><subject>Hydrocortisone - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prolactin - blood</subject><subject>Psychiatric Status Rating Scales</subject><subject>Serotonin Uptake Inhibitors - pharmacology</subject><subject>Treatment Outcome</subject><issn>0940-1334</issn><issn>1433-8491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkUtLxDAUhYMozjj6A9xIcOGuevNo0y5lGB8w4MJxHdL2RjtMm5q0guCPNzoFwdWFj3MOFz5CzhlcMwB1EwAkZAkAT0CoPGEHZM6kEEkuC3ZI5lBISJgQckZOQtgCAEs5HJMZ41zyVOVz8vWM3g2uQ__aVNR0Na1db9pmAh2O3mFXu8pHRD2G3nUBA3WWtmaHtMY-wtB8IO3N0GA3BFqidR5_x4wd0FNDhzf0psdxiJur5YZWbvQBT8mRNbuAZ9NdkJe71Wb5kKyf7h-Xt-ukElwOiVUl8AxsrqDAVNkU0KaFiKBGmdVMKFVhbpFnqlDSgilRYoZpZevSYF6IBbna7_bevY8YBt02ocLdznToxqAVZ5AXLI3By3_BbXy0i79pziRL8yLLYojtQ5V3IXi0uvdNa_ynZqB_vOi9Fx296B8vmsXOxTQ8li3Wf41JhPgGyYCK9A</recordid><startdate>20020801</startdate><enddate>20020801</enddate><creator>Markianos, Manolis</creator><creator>Hatzimanolis, John</creator><creator>Lykouras, Lefteris</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20020801</creationdate><title>Serotonergic and dopaminergic neuroendocrine responses of male depressive patients before and after a therapeutic ECT course</title><author>Markianos, Manolis ; Hatzimanolis, John ; Lykouras, Lefteris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c324t-f7b0260f8709e57f50ef5930f8de46d1377ce8fe267974f0abe4e6e5cfdbae893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Clomipramine - pharmacology</topic><topic>Depressive Disorder, Major - blood</topic><topic>Depressive Disorder, Major - therapy</topic><topic>Dopamine Antagonists - pharmacology</topic><topic>Electroconvulsive Therapy - methods</topic><topic>Haloperidol - pharmacology</topic><topic>Humans</topic><topic>Hydrocortisone - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prolactin - blood</topic><topic>Psychiatric Status Rating Scales</topic><topic>Serotonin Uptake Inhibitors - pharmacology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Markianos, Manolis</creatorcontrib><creatorcontrib>Hatzimanolis, John</creatorcontrib><creatorcontrib>Lykouras, Lefteris</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>European archives of psychiatry and clinical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Markianos, Manolis</au><au>Hatzimanolis, John</au><au>Lykouras, Lefteris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serotonergic and dopaminergic neuroendocrine responses of male depressive patients before and after a therapeutic ECT course</atitle><jtitle>European archives of psychiatry and clinical neuroscience</jtitle><addtitle>Eur Arch Psychiatry Clin Neurosci</addtitle><date>2002-08-01</date><risdate>2002</risdate><volume>252</volume><issue>4</issue><spage>172</spage><epage>176</epage><pages>172-176</pages><issn>0940-1334</issn><eissn>1433-8491</eissn><abstract>Electroconvulsive therapy (ECT) is an effective treatment for major depressive illness, even for patients who do not respond to antidepressant drugs. According to the prevailing neurophysiological hypotheses for depression, it can be expected that an ECT therapeutic course modulates the responsivity of central neurotransmitter systems, but the results up to now have been inconclusive. To test such hypotheses, we studied possible changes in the serotonergic and in dopaminergic systems' responsivity in 11 male patients with major depression by performing neuroendocrine challenge tests before and after a therapeutic ECT course. Serotonergic responsivity was assessed by measuring the prolactin and cortisol responses to i. v. administration of the serotonin uptake inhibitor clomipramine (CMI test), and dopaminergic responsivity by measuring the prolactin responses to the dopamine receptor blocker haloperidol (HAL test), administered intramuscularly. The prolactin and cortisol responses during the first and the last ECT of the course (8 to 13 sessions) were also assessed. The CMI and HAL tests were also performed in 13 male healthy subjects. The prolactin responses to CMI were significantly blunted in the patient group compared to the control group, and remained unaltered at the end of the ECT course, although the depressive symptomatology was substantially reduced from 27.8 +/- 7.1 to 4.8 +/- 2.3 points in the Hamilton Depression Rating Scale. The cortisol responses to CMI were blunted before the ECT course compared to controls, but not after the course: there was a moderate increase of cortisol at + 30 min in the CMI test after the ECT course compared to that before ECT (p = 0.05). The prolactin and cortisol responses to the electrical stimulus during the first and the last ECT were identical. The strong therapeutic effect of ECT in depression, observed already at the end of the course, is not a result of considerable modifications in central serotonergic or dopaminergic responsivity, as revealed by the neuroendocrine challenge tests and the hormone responses to the electrical stimulus. The enhancement of the cortisol responses to CMI after the course may indicate a moderate increase in 5-HT1A receptor responsivity.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>12242578</pmid><doi>10.1007/s00406-002-0378-1</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0940-1334
ispartof European archives of psychiatry and clinical neuroscience, 2002-08, Vol.252 (4), p.172-176
issn 0940-1334
1433-8491
language eng
recordid cdi_proquest_miscellaneous_72108915
source MEDLINE; SpringerNature Journals
subjects Adult
Aged
Clomipramine - pharmacology
Depressive Disorder, Major - blood
Depressive Disorder, Major - therapy
Dopamine Antagonists - pharmacology
Electroconvulsive Therapy - methods
Haloperidol - pharmacology
Humans
Hydrocortisone - blood
Male
Middle Aged
Prolactin - blood
Psychiatric Status Rating Scales
Serotonin Uptake Inhibitors - pharmacology
Treatment Outcome
title Serotonergic and dopaminergic neuroendocrine responses of male depressive patients before and after a therapeutic ECT course
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T06%3A10%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serotonergic%20and%20dopaminergic%20neuroendocrine%20responses%20of%20male%20depressive%20patients%20before%20and%20after%20a%20therapeutic%20ECT%20course&rft.jtitle=European%20archives%20of%20psychiatry%20and%20clinical%20neuroscience&rft.au=Markianos,%20Manolis&rft.date=2002-08-01&rft.volume=252&rft.issue=4&rft.spage=172&rft.epage=176&rft.pages=172-176&rft.issn=0940-1334&rft.eissn=1433-8491&rft_id=info:doi/10.1007/s00406-002-0378-1&rft_dat=%3Cproquest_cross%3E690294651%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214158966&rft_id=info:pmid/12242578&rfr_iscdi=true